IPP Bureau

BioNTech co-founders launch new mRNA venture, aiming to revolutionize next-gen therapies
BioNTech co-founders launch new mRNA venture, aiming to revolutionize next-gen therapies

By IPP Bureau - March 14, 2026

The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission

Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds
Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds

By IPP Bureau - March 14, 2026

Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound

Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan
Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan

By IPP Bureau - March 14, 2026

Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema

Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug
Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug

By IPP Bureau - March 14, 2026

The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days

Almirall opens Shanghai hub to power dermatology innovation and China partnerships
Almirall opens Shanghai hub to power dermatology innovation and China partnerships

By IPP Bureau - March 14, 2026

The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development

Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA
Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA

By IPP Bureau - March 13, 2026

Marks significant milestone for breakthrough biologic to treat rare blood cancers

Punjab joins hands with Roche to roll out ‘NeuroSakhi’ for women with multiple sclerosis
Punjab joins hands with Roche to roll out ‘NeuroSakhi’ for women with multiple sclerosis

By IPP Bureau - March 12, 2026

The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab

Fortis launches 4 specialized clinics in Bengaluru to tackle under-discussed health issues
Fortis launches 4 specialized clinics in Bengaluru to tackle under-discussed health issues

By IPP Bureau - March 12, 2026

The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise

World Glaucoma Week: Experts sound alarm over millions of undiagnosed cases in India
World Glaucoma Week: Experts sound alarm over millions of undiagnosed cases in India

By IPP Bureau - March 12, 2026

Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally

BPL Medical Tech acquires South Korea’s Yozma BMtech
BPL Medical Tech acquires South Korea’s Yozma BMtech

By IPP Bureau - March 12, 2026

Launches advanced bone density systems in India & Dubai

India tackles rare diseases head-on at landmark summit in New Delhi
India tackles rare diseases head-on at landmark summit in New Delhi

By IPP Bureau - March 12, 2026

Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration

Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio
Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio

By IPP Bureau - March 12, 2026

The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth

NewcelX and Eledon join forces to advance potential Type 1 diabetes cure
NewcelX and Eledon join forces to advance potential Type 1 diabetes cure

By IPP Bureau - March 12, 2026

The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets

FDA nod to LifeVac De Novo, paving for next-generation anti-choking device
FDA nod to LifeVac De Novo, paving for next-generation anti-choking device

By IPP Bureau - March 12, 2026

The FDA classified LifeVac as a Class II medical device

Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial
Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial

By IPP Bureau - March 12, 2026

The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36

Latest Stories

Interviews

Packaging